Continuing to harvest a bounty of autumn approvals, AstraZeneca has picked up nods for its C5 inhibitor gefurulimab to treat ...
Japanese Big Pharma Eisai is teaming up with Boston-based digital health company Linus Health to create new “Brain Health ...
The FDA has issued a complete response letter to Summit Therapeutics, derailing the immediate U.S. launch of a drug class ...
Genentech has unlocked a new chapter in its patient-forward “Life Doesn’t Wait” campaign for hemophilia A drug Hemlibra with ...
Earlier this year, AZ fired another shot in bladder cancer when Imfinzi was cleared by the FDA alongside Bacillus ...
The FDA has quietly shelved the Commissioner’s National Priority Voucher (CNPV) pilot program, a controversial speedy review ...
With a positive classification from the DEA paving the way for Orzeyful’s U.S. launch on Thursday, Takeda is charting new ...
Shortly after locking down a world-first approval in China, Bayer is bringing its groundbreaking stroke prevention drug ...
Following a back-and-forth with the Pentagon this year, contracting juggernaut WuXi AppTec appears to have largely evaded its ...
The FDA has launched a safety investigation into Novartis’ gene therapy Zolgensma following reports of tumors in patients, as ...
Summit Therapeutics is gearing up for ivonescimab’s high-stakes FDA decision without its chief commercial officer (CCO) ...
Johnson & Johnson is gearing up to expand the commercial reach of Caplyta after scoring a second phase 3 victory in bipolar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results